{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:56:35Z","timestamp":1790106995202,"version":"4.0.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2026,3]]},"abstract":"\n Key Points<\/jats:title>\n \n \n \n Primary hyperoxaluria type 1 is a genetic disorder associated with hepatic oxalate overproduction, kidney failure, and systemic oxalosis.<\/jats:p>\n <\/jats:list-item>\n \n Lumasiran treatment for up to 60 months was associated with sustained reductions in urinary and plasma oxalate and encouraging clinical outcomes.<\/jats:p>\n <\/jats:list-item>\n \n Lumasiran's safety profile was acceptable with mild injection site reactions being the most common adverse events.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n Primary hyperoxaluria type 1 (PH1) is characterized by hepatic oxalate overproduction, kidney stones, and progressive kidney disease. Lumasiran is the first approved treatment for PH1.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n ILLUMINATE-A (NCT03681184) was a 60-month pivotal, phase 3, multinational clinical trial of lumasiran which consisted of a 6-month double-blind, placebo-controlled period (6M DB), followed by a treatment extension period of up to 54 months in which all patients received lumasiran. Eligible patients were aged \u22656 years with genetically confirmed PH1, eGFR \u226530 ml\/min per 1.73 m\n 2<\/jats:sup>\n , and mean 24-hour urinary oxalate (UOx) excretion \u22650.70 mmol\/24 h per 1.73 m\n 2<\/jats:sup>\n .\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 39 patients enrolled, 24 of 26 randomized to lumasiran in the 6M DB (lumasiran\/lumasiran group) and 13 of 13 randomized to placebo in the 6M DB (placebo\/lumasiran group) completed the study. Sustained reductions in 24-hour UOx were observed in both treatment groups. At month 60 relative to study baseline, the mean (SEM) 24-hour UOx percentage reductions were 54 (6) and 54% (8%) in the lumasiran\/lumasiran and placebo\/lumasiran groups, respectively, and the mean (SEM) plasma oxalate concentrations had decreased by 35 (5) and 38% (7%). eGFR remained stable through the end of the study in both treatment groups. Kidney stone event rates during the study were 0.47 (95% confidence interval, 0.36 to 0.62) and 0.54 (0.37 to 0.78) per patient-year in the lumasiran\/lumasiran group and placebo\/lumasiran group, respectively. Medullary nephrocalcinosis grade improved at the end of the study in 21 of 28 (75%) patients with nephrocalcinosis at baseline and an end of study assessment. The safety profile of lumasiran was acceptable. Injection site reactions were the most common adverse events during lumasiran treatment. Most adverse events were mild or moderate in severity.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Lumasiran treatment for up to 60 months in ILLUMINATE-A was associated with sustained reductions in UOx excretion and plasma oxalate concentration, encouraging clinical outcomes including stable eGFR in a population that would be expected to show eGFR decline, reduced kidney stone event rates, improved medullary nephrocalcinosis, and indications of improved health-related quality of life.<\/jats:p>\n Clinical Trial registry name and registration number: ClinicalTrials.gov NCT03681184.<\/jats:p>\n <\/jats:sec>\n \n Podcast<\/jats:title>\n This article contains a podcast at https:\/\/dts.podtrac.com\/redirect.mp3\/www.asn-online.org\/media\/podcast\/CJASN\/2026_03_18_CJASNMar.21.3.31820.mp3<\/jats:p>\n <\/jats:sec>","DOI":"10.2215\/cjn.0000000916","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T17:00:21Z","timestamp":1764867621000},"page":"377-388","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Final Results of the ILLUMINATE-A Phase 3 Clinical Trial of Lumasiran for Primary Hyperoxaluria 1"],"prefix":"10.2215","volume":"21","author":[{"given":"Yaacov","family":"Frishberg","sequence":"first","affiliation":[{"name":"Division of Pediatric Nephrology, Shaare Zedek Medical Center, Jerusalem, Israel and Faculty of Medicine, Hebrew University, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8481-9210","authenticated-orcid":false,"given":"Jeffrey M.","family":"Saland","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0202-5944","authenticated-orcid":false,"given":"John C.","family":"Lieske","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Du","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0439-4409","authenticated-orcid":false,"given":"Martin","family":"Coenen","sequence":"additional","affiliation":[{"name":"Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4838-9417","authenticated-orcid":false,"given":"Julien","family":"Hogan","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology Department, H\u00f4pital Robert-Debr\u00e9, APHP, Centre R\u00e9f\u00e9rence Maladie Rares MARHEA, ERKnet, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9902-0850","authenticated-orcid":false,"given":"Anne-Laure","family":"Sellier-Leclerc","sequence":"additional","affiliation":[{"name":"H\u00f4pital Femme M\u00e8re Enfant en Centre d'Investigation Clinique, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), Hospices Civils de Lyon, ERKnet, Bron, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap W.","family":"Groothoff","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2720-9325","authenticated-orcid":false,"given":"Cristin","family":"Kaspar","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4030-3044","authenticated-orcid":false,"given":"John M.","family":"Gansner","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally-Anne","family":"Hulton","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Birmingham Women's and Children's Hospital, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the ILLUMINATE-A study investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"issue":"7","key":"B1-20260416","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1056\/NEJMra1301564","article-title":"Primary hyperoxaluria","volume":"369","author":"Cochat","year":"2013","journal-title":"N Engl J Med."},{"issue":"11","key":"B2-20260416","doi-asserted-by":"crossref","first-page":"101115","DOI":"10.1016\/j.xkme.2025.101115","article-title":"Natural history of advanced primary hyperoxaluria type 1: a retrospective study","volume":"7","author":"Lieske","year":"2025","journal-title":"Kidney Med."},{"issue":"7","key":"B3-20260416","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2215\/CJN.13831119","article-title":"Primary hyperoxaluria: the patient and caregiver perspective","volume":"15","author":"Lawrence","year":"2020","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"B4-20260416","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1080\/13696998.2023.2176678","article-title":"Estimating health state utilities in primary hyperoxaluria type 1: a valuation study","volume":"26","author":"de Freitas","year":"2023","journal-title":"J Med Econ."},{"issue":"2","key":"B7-20260416","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40265-023-01987-1","article-title":"Lumasiran: a review in primary hyperoxaluria type 1","volume":"84","author":"Kang","year":"2024","journal-title":"Drugs."},{"issue":"13","key":"B9-20260416","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1","volume":"384","author":"Garrelfs","year":"2021","journal-title":"N Engl J Med."},{"issue":"7","key":"B10-20260416","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.ekir.2024.04.048","article-title":"Efficacy and safety of lumasiran in patients with primary hyperoxaluria type 1: results from a phase III clinical trial","volume":"9","author":"Saland","year":"2024","journal-title":"Kidney Int Rep."},{"issue":"3","key":"B11-20260416","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.gim.2021.10.024","article-title":"Phase 3 trial of lumasiran for primary hyperoxaluria type 1: a new RNAi therapeutic in infants and young children","volume":"24","author":"Sas","year":"2022","journal-title":"Genet Med."},{"issue":"4","key":"B12-20260416","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00467-022-05684-1","article-title":"Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial","volume":"38","author":"Hayes","year":"2023","journal-title":"Pediatr Nephrol."},{"issue":"2","key":"B14-20260416","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1053\/j.ajkd.2025.01.016","article-title":"Efficacy and safety of lumasiran for advanced primary hyperoxaluria type 1: 24-month follow-up of the phase 3 ILLUMINATE-C trial","volume":"86","author":"Sellier-Leclerc","year":"2025","journal-title":"Am J Kidney Dis."},{"issue":"2","key":"B15-20260416","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1523-1755.2004.00796.x","article-title":"Clinical implications of mutation analysis in primary hyperoxaluria type 1","volume":"66","author":"van Woerden","year":"2004","journal-title":"Kidney Int."},{"issue":"9","key":"B17-20260416","doi-asserted-by":"crossref","first-page":"481","DOI":"10.4155\/bio-2022-0227","article-title":"Quantification of oxalate by novel LC-MS\/MS: assay development, validation and application in lumasiran clinical trials","volume":"15","author":"Clausen","year":"2023","journal-title":"Bioanalysis."},{"issue":"9","key":"B18-20260416","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med."},{"issue":"3","key":"B19-20260416","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"B20-20260416","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s002470050539","article-title":"Observer reliability in grading nephrocalcinosis on ultrasound examinations in children","volume":"29","author":"Dick","year":"1999","journal-title":"Pediatr Radiol."},{"issue":"1","key":"B21-20260416","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"issue":"10","key":"B22-20260416","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res."},{"issue":"5","key":"B23-20260416","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF00451725","article-title":"Development of the kidney disease quality of life (KDQOL) instrument","volume":"3","author":"Hays","year":"1994","journal-title":"Qual Life Res."},{"issue":"2","key":"B24-20260416","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/00005650-199902000-00003","article-title":"The PedsQL: measurement model for the pediatric quality of life inventory","volume":"37","author":"Varni","year":"1999","journal-title":"Med Care."},{"issue":"3","key":"B25-20260416","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","article-title":"A 12-Item short-form health survey: construction of scales and preliminary tests of reliability and validity","volume":"34","author":"Ware","year":"1996","journal-title":"Med Care."},{"issue":"3","key":"B26-20260416","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/ki.2014.298","article-title":"Nephrocalcinosis is a risk factor for kidney failure in primary hyperoxaluria","volume":"87","author":"Tang","year":"2015","journal-title":"Kidney Int."},{"issue":"5","key":"B27-20260416","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s40620-023-01611-1","article-title":"Is withdrawal of nocturnal hyperhydration possible in children with primary hyperoxaluria treated with RNAi?","volume":"36","author":"Biebuyck","year":"2023","journal-title":"J Nephrol."},{"key":"B28-20260416","doi-asserted-by":"crossref","first-page":"111487","DOI":"10.1016\/j.jclinepi.2024.111487","article-title":"Systematic review reveals that EQ-5D minimally important differences vary with treatment type and may decrease with increasing baseline score","volume":"174","author":"Cheng","year":"2024","journal-title":"J Clin Epidemiol."},{"key":"B30-20260416","doi-asserted-by":"crossref","first-page":"703305","DOI":"10.3389\/fmed.2021.703305","article-title":"Primary hyperoxaluria type 1 disease manifestations and healthcare utilization: a multi-country, online, chart review study","volume":"8","author":"Wang","year":"2021","journal-title":"Front Med (Lausanne)."},{"issue":"3","key":"B31-20260416","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1053\/j.ajkd.2022.01.428","article-title":"Estimated GFR slope across CKD stages in primary hyperoxaluria type 1","volume":"80","author":"Singh","year":"2022","journal-title":"Am J Kidney Dis."},{"issue":"2","key":"B32-20260416","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.1016\/j.ekir.2022.01.465","article-title":"POS-438 long-term treatment with lumasiran: results from the phase 2 open-label extension study","volume":"7","author":"Magen","year":"2022","journal-title":"Kidney Int Rep."},{"issue":"2","key":"B33-20260416","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.ajkd.2022.05.012","article-title":"Lumasiran for advanced primary hyperoxaluria type 1: phase 3 ILLUMINATE-C trial","volume":"81","author":"Michael","year":"2023","journal-title":"Am J Kidney Dis."}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000000916","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:37:02Z","timestamp":1786369022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000000916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.0000000916","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"2025-05-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}